rti 121 has been researched along with oxidopamine in 5 studies
| Studies (rti 121) | Trials (rti 121) | Recent Studies (post-2010) (rti 121) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 64 | 1 | 11 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | rti 121 (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bohn, MC; Connor, B; Elsworth, JD; Kozlowski, DA; Schallert, T; Tillerson, JL; Unnerstall, JR | 1 |
| Bordia, T; Huang, LZ; Michael McIntosh, J; Parameswaran, N; Quik, M | 1 |
| Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Bordia, T; Perez, XA; Quik, M; Zhang, D | 1 |
5 other study(ies) available for rti 121 and oxidopamine
| Article | Year |
|---|---|
Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Topics: Aging; Animals; Autoradiography; Carrier Proteins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Genetic Therapy; Genetic Vectors; Glial Cell Line-Derived Neurotrophic Factor; Male; Membrane Glycoproteins; Membrane Transport Proteins; Microinjections; Motor Activity; Nerve Growth Factors; Nerve Tissue Proteins; Neurons; Neurotransmitter Agents; Oxidopamine; Parkinson Disease, Secondary; Presynaptic Terminals; Rats; Rats, Inbred F344; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Analysis of Variance; Animals; Autoradiography; Cocaine; Conotoxins; Corpus Striatum; Cotinine; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Iodine Isotopes; Male; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Nicotine; Oxidopamine; Protein Binding; Rats; Rats, Sprague-Dawley; Saimiri; Substantia Nigra; Time Factors | 2009 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics | 2013 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; Sympatholytics | 2017 |